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Key messages
What is already known about this subject?
 ► Work productivity is significantly affected by 
axial spondyloarthritis (axSpA).
What does this study add?
 ► The ability to work is of prime importance to 
patients with axSpA.
 ► This is the first paper to demonstrate that 
individuals with axSpA living in rural areas 
report a greater impact of their disease on their 
ability to work.
 ► This mixed- methods study highlights the 
relevance and nature of clinical and contextual 
factors, and offers new insights into how 
features of occupations, individuals and 
workplaces influence work disability in axSpA.
How might this impact on clinical practice or 
future developments?
 ► Impaired ability to work for those living in rural 
settings has important consequences as the 
ageing, multimorbid population is increasing 
faster in rural areas and people are working to 
older ages.
 ► New comprehensive work measures are needed 
to capture important contextual factors and 
the impact of long- term conditions in the 
workplace.
 ► Future European League Against Rheumatism 
axSpA recommendations should include 
workability as a target for management to 
optimise quality of life in patients with axSpA.
ABSTRACT
Objective To examine differences in clinical and 
patient- reported outcomes, including work, in individuals 
with axial spondyloarthritis (axspa) living in rural and 
urban settings.
Methods Using a sequential, explanatory mixed- 
method design, data from the British society for 
Rheumatology Biologics Register for ankylosing 
spondylitis were used to (1) characterise participants 
with axspa living in rural and urban areas and (b) assess 
any differences in outcome after commencement of 
biologic therapy (phase 1). semistructured interviews 
(phase 2) further explored the results from phase 1.
Results patients with axspa living in rural areas were 
older and more likely to work in a physical job. among 
patients prescribed biologics, there were no differences 
in response to biologics, but after adjustment for age, 
sex and local area deprivation rural dwellers reported 
more presenteeism and overall work impairment. Work 
effects could be explained by accounting for individual 
differences in disease activity, fatigue, physical function 
and job type. interviews highlighted the complex 
relationship between clinical factors, contextual factors 
(work environment, job demands) and work disability. 
The ability to work and flexibility in terms of what, 
when and how tasks are undertaken were important. 
support from employers was variable and healthcare 
professionals were often perceived as unsupportive.
Conclusions patients with axspa living in rural 
areas report a greater impact of their disease on work 
productivity. new measures are needed to capture 
important contextual factors and comprehensively 
determine the impact of long- term conditions on work. 
Future European league against Rheumatism axspa 
recommendations should include support to work as a 
target to optimise quality of life in patients with axspa.
InTROduCTIOn
The ability to participate in the labour market is not 
only important economically, but work also has a 
positive impact on social and psychological health.1 
While absenteeism and job loss are the endpoints of 
work disability, these are only the tip of the iceberg 
because musculoskeletal disorders have a substan-
tially greater impact on worker productivity.2
According to one estimate, work disability affects 
up to 30% of patients with axial spondyloarthritis 
(axSpA).3 Compared with the general population, 
individuals with axSpA are three times more likely 
to withdraw from work, especially from physically 
demanding jobs.4 Other factors associated with 
work disability in axSpA include older age, longer 
disease duration, functional impairment, pain, 
fatigue, low mood, comorbidity and lower educa-
tional attainment.5 6 We have previously shown that 
job type and disease activity predict presenteeism 
(being in the workplace but performing below their 
usual levels (productivity loss) because of ill health), 
which in turn predicts absenteeism and job loss.7 
While biologic therapy reduces presenteeism and 
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improves functional capacity in axSpA, significant unmet need 
remains in terms of work disability.8
There is good evidence that supportive work environments 
are important to enable individuals with health conditions to 
work; however, not all workplaces are created equally, and in 
particular there are important rural–urban differences.9 While 
employment rates may be higher, incomes tend to be lower in 
rural areas, with restricted choice and opportunities for career 
advancement.10 Rural workers more often work in smaller busi-
nesses and industries, and manual, lower paid jobs are more 
prevalent. Such jobs may be less flexible and have more restric-
tions preventing adjustments (eg, paid leave) than higher- income 
jobs.
With the ageing, multimorbid population increasing faster in 
rural areas,11 12 and people working to older ages, understanding 
the relationship between rurality, health and work outcomes 
is important to ensure that individuals with rheumatic disease 
are supported to live and work well. A number of studies have 
highlighted inadequate access to specialist healthcare services for 
those with rheumatic and musculoskeletal disease (RMD) living 
in rural and remote locations.13–16 However, in a recent system-
atic review of the literature, we found very limited evidence as 
to whether outcomes are poorer for individuals with rheumatic 
disease living in rural settings.17 No eligible studies examined 
work outcomes. All studies were relatively small, rarely provided 
a definition of rural status, and did not measure aspects related 
to rurality, such as access to services, patient preferences or 
the work environment. Furthermore, important differences in 
socioeconomic status between rural and urban areas were noted 
but not usually adjusted for when comparing outcomes, making 
it difficult to determine whether rurality is an independent 
predictor of poor outcome in RMD or a surrogate marker for 
socioeconomic status.17
This study aims to examine differences in clinical and patient- 
reported outcomes, including work outcomes, in individuals 
with axSpA living in rural and urban settings, using a sequential, 
explanatory mixed- method design.18 First, data from the British 
Society for Rheumatology Biologics Register for Ankylosing 
Spondylitis (BSRBR- AS) will be used to (1) describe the char-
acteristics of participants with axSpA living in rural and urban 
areas and (2) assess any differences in outcome after commence-
ment of biologic therapy between these groups (phase 1). This 
will be followed by semistructured interviews in a subset of 
registry participants (phase 2) to further explore the results from 
phase 1.
MATeRIAlS And MeTHOdS
Phase 1: BSRBR-AS data
The BSRBR- AS is a prospective cohort study which recruited 
biologic- naïve adult patients meeting the Assessment of Spon-
dyloArthritiS (ASAS) criteria for axSpA, from 83 centres across 
Great Britain in 2012–2017.19 The full study protocol has been 
previously published.20 This analysis uses clinical and patient- 
reported data from recruitment (baseline) for all subjects and 
prospective data from the subcohort commencing biologic 
therapy at baseline. Their ‘outcome’ is measured at the first time 
point between 6 weeks and 12 months after starting therapy. 
Clinical data were collected during rheumatology appointments 
and patient- reported outcomes via postal questionnaires.
Clinical data
The following were systematically collected: age, gender, prev-
alent extraspinal manifestations, which medical imaging was 
undertaken (X- ray and MRI), medication (non- steroidal anti- 
inflammatory drugs (NSAIDS) and disease- modifying antirheu-
matic drugs (DMARDS) use in previous 6 months), human 
leukocyte antigen B27 (HLA- B27) status, and Bath Ankylosing 
Spondylitis Metrology Index score (scored from 0 (least) to 10 
(most severe)).21 We calculated the lag time from the year of 
symptom onset to the date of first rheumatology assessment.
Patient-reported measures
The questionnaires enquired about educational level, smoking 
status, alcohol intake, employment status, and among those 
employed the job type (mainly desk/sedentary or mainly phys-
ical/labour- intense). The Work Productivity and Activity Impair-
ment Specific Health Problem indicated the proportion of 
work missed (absenteeism) or impaired (presenteeism) over the 
previous week, measure of overall work impairment (absen-
teeism and presenteeism) and other activity impairment outside 
of work (all scored 0%–100%).22 23 Quality of life was assessed 
by the Ankylosing Spondylitis Quality of Life Index (scored 
from 0 (best) to 18 (worst)24) and the Short Form-12 Physical 
and Mental Component Scores (scored from 0 (worst) to 100 
(best)25). The Hospital Anxiety and Depression Scale (HADS) 
indicated mental health (scored from 0 (best) to 21 (worst)26), 
while fatigue and sleep disturbance were measured using the 
Chalder Fatigue Scale (from 0 (best) to 11 (worst)) and Jenkins 
Sleep Evaluation Questionnaire (from 0 (best) to 20 (worst)), 
respectively.27 28 Spinal pain was assessed using a 10 cm Visual 
Analogue Scale and the Bath Ankylosing Spondylitis indices used 
to measure disease activity (BASDAI), physical function (BASFI) 
and patient global score (BASG) (all scored from 0 (best) to 10 
(worst)).29–31 Postcodes, provided by participants on returned 
questionnaires, were used to:
 ► Derive a measure of local area deprivation (from 1 (most 
deprived) to 5 (least deprived))32 33 in order to adjust for 
local- level deprivation.
 ► Categorise participants into those living in rural and urban 
areas by the 2011 UK Census.32 33 Rural areas were catego-
rised as settlements of less than 3000 people.
Phase 2: semistructured interviews
Semistructured telephone interviews were conducted with a 
subset of BSRBR- AS registry participants from phase 1 who 
had consented to participate in further studies. The focus and 
content of the interviews were determined by the results of 
phase 1. As differences in presenteeism emerged as an important 
factor, the interview topic guide (see online supplementary text) 
was developed to explore this further, informed by the find-
ings from phase 1 and review of existing qualitative literature 
on work outcomes in axSpA and other rheumatic diseases, as 
well as input from patient partners. BSRBR- AS participants were 
purposively selected for interview based on employment status, 
job type, age, disease duration and urban or rural location across 
seven geographical sites within the UK. Interviews explored 
interactions between aspects of disease (such as activity, func-
tion, fatigue, medications), job characteristics and work environ-
ment, and their impact on work. We also examined the impact 
of work disability on quality of life, career choice and progress 
and support to work. All interviews were conducted by a single 
researcher (KS) previously unknown to study participants.
data analysis
The characteristics of patients living in urban and rural areas were 
described in terms of mean (and SD) for continuous variables and 
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proportions for categorical variables, with differences assessed 
via Mann- Whitney and χ2 tests. Relationships between living in 
a rural area and work outcome (absenteeism, presenteeism and 
overall work impairment) were further quantified using linear 
regression models, adjusted for age, gender, local area depriva-
tion and baseline scores (for patient- reported measures). Sequen-
tial adjustments were then made for additional factors previously 
found associated with presenteeism (disease activity (BASDAI), 
fatigue, job type and physical function (BASFI)).34 Results are 
given as β coefficients and 95% CI. Among those commencing 
a biologic agent, the potential relationship between rural living 
and outcome at 12- month follow- up was assessed. Outcome was 
evaluated in two main ways:
 ► Meeting response, as defined by the ASAS improvement 
criteria (ASAS20 and ASAS40).35 36
 ► Patient- reported measures (adjusted for baseline score): 
disease activity, physical function, quality of life, fatigue, 
sleep disturbance, anxiety, depression, activity impairment 
and work outcomes (presenteeism, absenteeism and overall 
work impairment).
Analyses were conducted on STATA V.15.0 using the August 
2017 version of the BSRBR- AS data set.
Interviews were audio- recorded, transcribed verbatim and 
entered into NVivo V.12 software to facilitate data organisa-
tion and retrieval. Interviews were analysed thematically by KS, 
supported by RJH, using a combination of anticipated themes 
(informed by the topic guide) and inductively derived coding.37 
The analytical process involved (1) familiarisation with data and 
initial coding; (2) organisation of codes according to similarity 
of meaning; (3) development and review of (sub)themes; and 
(4) definition of (sub)themes and their interactions. Emerging 
analysis was discussed and developed with all authors. Data satu-
ration was deemed to have been achieved through thematic and 
code saturation.38
Integration of data
Quantitative and qualitative data were integrated at several 
stages; analysis of the BSRBR- AS data in phase 1 was used to 
identify interview participants and to determine the focus and 
content of interviews in phase 2. Integration of findings from 
phase 1 and 2 provided a deeper understanding of the impact of 
axSpA on work and role of contextual factors.
Patient and public involvement
Patient representatives on the BSRBR- AS strategy group iden-
tified work and the impact of geography on health outcomes 
as a key research priority. We developed this study to explore 
this. The interview topic guide was developed with input from 
patient partners. At the end of the study, the BSRBR- AS strategy 
group commented on findings and contributed to the dissemi-
nation plan.
ReSulTS
BSRBR-AS registry
Baseline characteristics of study population
There were 2390 BSRBR- AS participants eligible for the current 
study, of which 24% (n=579) lived in a rural area. Rural dwellers 
were older (50.5 vs 47.4 years), less likely to be current smokers 
(15% vs 21%) and more likely to be in a predominantly physical/
labour- intense occupation (54% vs 44%) (table 1).
Rural participants scored better than urban dwellers in terms 
of local area deprivation, mental health (SF-12 Mental Compo-
nent Score, HADS anxiety, HADS depression) and fatigue. The 
groups were not significantly different in gender distribution, 
alcohol use, medication, prevalent extraspinal manifestations, 
disease activity, physical function, spinal mobility, quality of life 
or sleep disturbance.
After adjusting for age, gender and local area deprivation, 
living in rural areas was associated with employment in a mainly 
physical/labour- intensive job (OR. 2.0 (95% CI 1.5 to 2.6)). 
Rural patients indicated that they experienced higher levels of 
work presenteeism and overall work impairment compared with 
urban patients (5.0% (1.3% to 8.7%) and 5.5% (1.6% to 9.4%)). 
After additional adjustment for disease activity (coefficient 2.0 
(95% CI −0.7 to 4.7)), fatigue (2.2 (–0.5 to 4.8)), job type (1.4 
(−1.2 to 4.0)) and physical function, the relationship between 
presenteeism and rural dwelling was attenuated (0.5 (−2.0 to 
3.1)) (figure 1).
Association between living in a rural area and outcome of treatment 
with biologic therapy
Of the BSRBR- AS participants, 421 commenced biologic therapy 
and provided information at 12- month follow- up. Of these, 26% 
lived in a rural area. Similar differences were noted between the 
urban and rural participants commencing a biologic therapy, 
to those seen in the whole BSRBR- AS cohort. Biologic patients 
living in rural areas were older, exhibited lower levels of local 
area deprivation and a longer referral delay but lower anxiety 
scores (see online supplementary table S1). They were more 
likely to have been HLA- B27- typed and work in a physical job. 
The proportion of biologic patients in employment was similar 
between rural and urban dwellers (38.7% and 36.5%, respec-
tively) and to that observed in the whole BSRBR- AS cohort. 
Similar rates of response in ASAS20 and ASAS40 criteria were 
seen among rural and urban patients at 12- month follow- up (OR 
of response in rural patients 0.9 (0.6 to 1.5) and 1.0 (0.6 to 1.6), 
respectively) (table 2).
Moreover, there were no significant differences in disease 
activity, physical function, quality of life, fatigue, sleep distur-
bance, anxiety, depression or activity impairment (outside work) 
at 12 months between rural and urban patients. However, among 
those currently in employment, living in a rural area was associ-
ated with a higher proportion of presenteeism and overall work 
impairment compared with urban dwellers (coefficient 10.0% 
(2.9% to 17.1%) and 10.4% (2.6% to 18.1%)). However, on 
additional adjustment for disease activity (coefficient 4.9% (95% 
CI −0.4% to 10.2%)), fatigue (5.3% (−0.1% to 10.7%)), job 
type (4.4% (−1.0 to 9.8%)) and physical function (3.9% (−1.4% 
to 9.1%)), the relationship between presenteeism and rural 
dwelling was also attenuated in the biologics cohort (figure 2).
Interview findings
We conducted 30 semistructured telephone interviews with a 
subset of patients drawn from the BSRBR- AS registry; 77% were 
of working age across a broad spread of occupations, 80% were 
male, 60% had disease duration >11 years and 60% lived in a 
rural location (see online supplementary table S2).
People with axSpA want to work
Many interviewees reported benefits of being in work. In partic-
ular, work was important in terms of self- identity, providing 
social interactions as well as financial security.
…I enjoy the contact [with customers] and talking about the work, 
I do enjoy that really and how we’re going to solve a problem be-
tween us. Yeah, so I think I would really miss that actually. (40-002)
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Table 1 Baseline characteristics of urban and rural dwellers
urban dwellers Rural dwellers
difference
(rural vs urban)
demographic characteristics n Mean (Sd) n Mean (Sd) Mean difference 
(95% CI)
Age* Years 1810 47.4 (14.5) 579 50.5 (13.9) 3.1 (1.7 to 4.4)
Local area deprivation* 1 (most) – 5 (least) 1811 3.0 (1.4) 579 3.8 (1.0) 0.8 (0.7 to 0.9)
n % n % Mean % difference 
(95% CI)
Gender Male 1242 68.6 394 68.0 −0.6 (−8.3 to 7.1)
Smoking status* Never 597 43.8 206 45.2 1.4 (−5.6 to 8.4)
Ex 475 34.8 184 40.3 5.5 (−1.0 to 12.0)
Current 291 21.3 66 14.5 −6.8 (−10.9 to −2.7)
Alcohol Never 94 6.9 30 6.6 −0.3 (−2.8 to 2.2)
Ex 243 17.9 78 17.1 −0.8 (−5.1 to 3.5)
Current 1021 75.2 348 76.3 1.1 (−8.1 to 10.3)
Employed Yes 528 38.4 175 37.9 −0.5 (−6.9 to 5.9)
Job type* Mainly desk/sedentary 465 56.4 127 45.8 −10.6 (−20.0 to −1.2)
Mainly physical/labour- intense 360 43.6 150 54.2 10.6 (0.9 to 20.3)
Clinical characteristics
HLA- B27 status* Tested 1203 66.4 412 71.2 4.8 (−3.0 to 12.6)
NSAID Prescribed (last 6 months) 1340 74.6 431 75.0 0.4 (−7.7 to 8.5)
DMARD Prescribed (last 6 months) 170 13.4 63 15.7 2.3 (−1.9 to 6.5)
Images taken X- ray 1493 82.4 490 84.6 2.2 (−6.3 to 10.7)
MRI* 1225 67.6 361 62.3 −5.3 (−12.7 to 2.1)
ESM (history) Uveitis present 433 24.1 128 22.3 −1.8 (−6.2 to 2.6)
Psoriasis present 203 11.3 59 10.3 −1.0 (−3.9 to 1.9)
IBD present 190 10.6 54 9.4 −1.2 (−4.0 to 1.6)
Dactylitis present 69 3.8 25 4.3 0.5 (−1.2 to 2.2)
Enthesitis present 174 9.9 65 11.3 1.4 (−1.36 to 4.4)
PJD present 320 17.8 116 20.2 2.4 (−1.7 to 6.5)
Patient- reported characteristics
n Mean (Sd) n Mean (Sd) Mean difference 
(95% CI)
Referral delay† Years 1784 7.8 (9.8) 571 8.6 (10.2) 0.8 (−0.2 to 1.7)
Disease activity BASDAI: 0 (best) – 10 (worst) 1364 4.9 (2.6) 454 4.7 (2.5) −0.2 (−0.4 to 0.1)
Physical function BASFI: 0 (best) – 10 (worst) 1374 4.6 (2.9) 461 4.7 (2.8) 0.1 (−0.4 to 0.2)
Spinal mobility BASMI: 0 (best) – 10 (worst) 1288 3.9 (2.0) 453 3.9 (1.9) 0 (−02 to 0.3)
Global health BASG: 0 (best) – 10 (worst) 1364 5.2 (2.8) 458 4.9 (2.7) −0.3 (−0.5 to 0.1)
Spinal pain VAS: 0 (best) – 10 (worst) 1366 4.5 (3.0) 457 4.4 (2.9) −0.1 (−0.4 to 0.2)
SF-12 MCS* Scored: 0 (worst) – 100 (best) 1332 45.3 (11.6) 455 47.6 (11.1) 2.3 (1.1 to 3.5)
SF-12 PCS Scored: 0 (worst) – 100 (best) 1332 38.4 (11.9) 455 38.1 (11.9) −0.3 (−1.6 to 1.0)
Quality of life ASQoL: 0 (best) – 18 (worst) 1362 8.8 (5.8) 458 8.3 (5.5) −0.5 (−1.1 to 0.1)
Anxiety* HADS: 0 (best) – 21 (worst) 1362 7.9 (4.8) 455 7.1 (4.6) −0.8 (−1.3 to −0.3)
Depression* HADS: 0 (best) – 21 (worst) 1362 6.1 (4.2) 455 5.5 (4.1) −0.6 (−1.1 to −0.2)
Sleep disturbance Jenkins Sleep Evaluation 
Questionnaire: 0 (best) – 20 
(worst)
1368 10.5 (6.2) 461 10.0 (6.4) −0.5 (−1.2 to 0.1)
Fatigue* CFS: 0 (best) – 11 (worst) 1379 4.3 (3.8) 463 3.9 (3.7) −0.4 (−0.8 to −0.04)
Work absenteeism % 760 6.8 (20.2) 258 5.8 (17.6) −1.0 (−3.7 to 1.8)
Work presenteeism % 758 31.2 (27.1) 258 31.8 (25.8) 0.6 (−3.2 to 4.4)
Overall work impairment % 737 32.3 (28.0) 251 33.3 (27.2) 1.0 (−3.0 to 5.0)
Activity impairment % 1350 44.4 (30.0) 452 42.5 (28.5) −1.9 (−5.1 to 1.2)
*Indicates significant difference between urban and rural dwellers (p<0.05).
†Delay from symptom onset to first referral to specialist clinic.
ASQoL, Ankylosing Spondylitis Quality of Life Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASG, Bath 
Ankylosing Spondylitis Patient Global Score; BASMI, Bath Ankylosing Spondylitis Metrology Index; CFS, Chalder Fatigue Scale; DMARD, disease- modifying antirheumatic drugs; 
ESM, extraspinal manifestations; HADS, Hospital Anxiety and Depression Scale; IBD, inflammatory bowel disease; NSAID, non- steroidal anti- inflammatory drug; PJD, peripheral 
joint disease; SF-12 MCS, Short Form-12 Mental Component Score; SF-12 PCS, Short Form-12 Physical Component Score; VAS, Visual Analogue Scale.
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Figure 1 Relationship between presenteeism and living in a 
rural area, adjusted for increasing number of factors. BASDAI, Bath 
Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing 
Spondylitis Functional Index.
Table 2 Associations with living in rural areas and outcome among 
those commencing a biologic therapy
univariable regression analyses, adjusted for age gender, 
local area deprivation and baseline score (as appropriate)
Categorical outcomes OR 95% CI
ASAS response criteria ASAS20 met 0.93 (0.59 to 1.47)
ASAS40 met 0.96 (0.58 to 1.57)
Continuous outcomes Coef 95% CI
Disease activity BASDAI: 0 (best) – 10 (worst) −0.05 (−0.56 to 0.46)
Physical function BASFI: 0 (best) – 10 (worst) 0.17 (−0.46 to 0.50)
Quality of life ASQoL: 0 (best) – 18 (worst) 0.06 (−0.99 to 1.11)
Fatigue CFS: 0 (best) – 11 (worst) −0.16 (−0.94 to 0.62)
Sleep disturbance Jenkins Sleep Evaluation 
Questionnaire: 0 (best) – 20 
(worst)
0.32 (−0.80 to 1.44)
Anxiety HADS: 0 (best) – 21 (worst) 0.22 (−0.50 to 0.95)
Depression HADS: 0 (best) – 21 (worst) −0.35 (−1.07 to 0.37)
Work absenteeism % 1.52 (−3.78 to 6.81)
Work presenteeism* % 9.96 (2.85 to 17.06)
Overall work impairment* % 10.37 (2.63 to 18.10)
Activity impairment % 0.74 (−4.84 to 6.32)
*Indicates significant difference between urban and rural dwellers (p<0.05).
ASAS, Assessment in Ankylosing Spondylitis; ASQoL, Ankylosing Spondylitis Quality of Life Index; 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis 
Functional Index; CFS, Chalder Fatigue Scale; Coef, β coefficients; HADS, Hospital Anxiety and 
Depression Scale.
Figure 2 Relationship between presenteeism at follow- up and living 
in a rural area among biologic patients, adjusted for increasing number 
of factors. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; 
BASFI, Bath Ankylosing Spondylitis Functional Index.
Ability to work negatively affected by axSpA
Nearly three- quarters of interviewees recognised that axSpA 
caused them challenges at work. In particular, reduced mobility, 
pain and fatigue impacted physical and mental function at work:
I’m a retail manager…there is a lot of physical work in it as well and 
sort of mental work with it and before the injections I did find it 
sort of like hard, I was restricted with what I could carry and what 
I can move about and things like that. (30-001)
It’s quite rough driving about in the machines so sometimes it’s 
really sore. (10-005)
The impacts were sufficiently important that they influenced 
decisions about type of work, choice of career and working 
hours:
I’ve always kind of done catering jobs, so I’ve been on my feet…
but I don’t do that anymore in terms of obviously I can’t be on my 
feet for that length of time, and now I work in an office. (60-004)
I don’t think I would cope with full- time, just because I am very 
sore, I do get very tired. I think full- time is unrealistic for me at the 
minute, anyway. (60-001)
Job demand-control-support and flexibility at work
Job titles and simplistic classification of occupations, for 
example, sedentary/manual, failed to fully capture the physical 
demands of different types of work. No matter what the physical 
demands, however, people with axSpA who reported autonomy 
and control to perform their job or specific tasks how and when 
they wanted to were able to cope better at work. Employer flex-
ibility and adjustments to working practices enabled participants 
to continue to work, when they would otherwise have been 
unable:
If I’m feeling poorly or whatever I phone my manager and we 
can…I’ll just do some work at home. (30-002)
They’ve been really good…they got me a more ergonomic chair 
and I’m allowed to get up if…when I need to, sort of every half an 
hour I’ll get up and have a little stretch and walk down the corridor 
and then come back to my desk. (60-004)
Support, from managers or colleagues, was another enabling 
factor:
If there’s something that needs doing fairly immediately and time is 
of the essence then someone will help me, or someone else has to 
do it and I’ll go and do something else. (20-001)
More challenges were experienced in workplaces where 
inflexibility was perceived:
The management within the company is very old- school and 
they’re not very flexible at all. They don’t promote working from 
home, they don’t like people coming in late, they don’t like people 
coming in early…the management have got clean bills of health, so 
they expect everyone else to. (10-001)
A number of participants reported that it was the lack of 
support and flexibility that had resulted in them leaving some 
jobs. Moreover, some types of work demands could be perceived 
as encouraging presenteeism even when participants were feeling 
unwell:
Part of the job was interviewing people…if you’re feeling unwell 
or not, you didn’t want to let people down by not turning up to 
interviews. I think that’s what drove it on. (30-003)
Contracts and entitlement to sick pay emerged as important 
factors influencing presenteeism. Some participants reflected 
that their experiences with Human Resources seemed punitive 
and disciplinary, rather than supportive, with a lack of under-
standing of the difference between minor illnesses and a long- 
term condition like axSpA:
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There wasn’t any sort of relaxation, it was like, “Right, you’ve been 
off for so many days and these days, and you’re off again,” and they 
total the counts…it was unpleasant and to me, unnecessary…not a 
question of I’ve got a cold; I’ve got a major problem, you know? 
(30-003)
Disclosure to employers
Many participants had disclosed their condition to their 
employer because of the medication they were taking or because 
they needed time off to attend appointments, or their condi-
tion was physically obvious. However, employees reflected that 
there was reluctance on both sides to initiate discussion about 
the condition unless there were issues around work perfor-
mance. Employers reportedly did not understand or care about 
the condition, and axSpA was often misunderstood as simply ‘a 
bad back’.
I don’t think they’d understand what it was anyway, it would just 
be words on a piece of paper…until it affected my time, my atten-
dance, I don’t think they’d care. (50-005)
Others openly disclosed their condition, keen to ‘prove’ that 
employees with disabilities were a valuable asset:
That’s why I like telling people that I’ve got a condition because…
my colleagues are surprised because you don’t see any difference in 
my performance to anybody else’s. (30-002)
Commuting to and from work
Despite sampling from rural and urban postcodes, most of 
the interviewees who lived in rural settings worked in urban 
settings. Adaptations to driving and commuting to work were 
commonplace:
I drive an automatic car now…I couldn’t manage without it…actu-
ally living here without a car in this particular location that we’re 
in, you would find it very difficult because we’re not on main bus 
routes…you need a car. (10-003)
The only trouble I do have is getting out, I find the car parking 
spaces a little bit too small if I can’t open the door wide to get out 
of the car. (60-003)
Effects of medication on work
Many participants reported that biologic drugs improved their 
ability to work. In contrast, use of opiate- containing analge-
sics caused problems, especially for those driving or operating 
machinery:
I cannot take my like heavy pain killers when I am operating my 
machinery. If it’s really really sore I have to put up with it or can’t 
go to work if it’s bad. (10-005)
Role of the rheumatology team
Participants rarely discussed work issues with their rheumatolo-
gist. Consultations were mainly focused around medical aspects 
of the disease and medications. Many felt that their healthcare 
professionals could be more proactive in discussing work issues, 
while a few reported that their care team provided support and 
encouragement to work:
They ask me every time I go. “Are you okay for work?”. [the Con-
sultant] says…“it’s better for you if you can carry on because you’ve 
got something to look forward to and to get up and get yourself 
going.” So yes, they’re very supportive. (20-004)
dISCuSSIOn
Patients with axSpA living in rural areas were older, more likely 
to work in a physical job and reported more presenteeism and 
overall work impairment than urban dwellers. We found no 
overall differences in disease activity at baseline/follow- up, but 
adjustment at an individual level for clinical factors (disease 
activity, fatigue, physical function) and a crude measure of job 
type attenuated differences in work productivity. In the subset 
of patients with axSpA prescribed biologics, there were no 
differences in response to biologics, but after adjustment for 
age, sex and local area deprivation rural dwellers still reported 
more presenteeism and overall work impairment at follow- up. 
These work effects could similarly be explained by accounting 
for differences in disease activity, fatigue, physical function and 
job type.
Interviews with a subset of BSRBR- AS participants illustrated 
the complex relationship between clinical factors, contextual 
factors (such as working conditions, job demands) and work 
disability. The ability to work is of prime importance to patients 
and employment had health benefits. Flexibility in terms of 
what, when and how tasks are done is important. Job titles failed 
to reflect the heterogeneity of current working conditions: both 
physical and mental demands and the level of autonomy afforded 
to individuals to carry out their work as their health fluctuates. 
There was important variation in support offered by employers 
and how little people with axSpA perceive they can seek help 
with work from healthcare professionals. Together these find-
ings suggest that work factors, health and healthcare are causing 
differential impacts on rural dwellers.
Our study has some limitations. We acknowledge that there 
are differences between rural and urban populations and have 
previously shown differences between working and non- working 
persons.8 However, in this study we have specifically focused 
on differences in working and non- working people in rural 
and urban areas. These were exploratory analyses, prioritised 
by patient representatives, which sought to investigate the full 
range of work outcomes, making no a priori assumptions. Future 
studies should focus on the effects of mediating factors and their 
role on the relationship between rurality and work outcomes, 
and will need to take account of the effect of multiple testing. 
However, irrespective of potential interactions between factors, 
poorer work outcomes for rural dwellers have important impli-
cations for patient care. We also recognise that presenteeism and 
work impairment data are skewed. Importantly, we have only 
used these data to assess descriptive differences between urban/
rural patients and used linear regression to look at outcomes, 
and therefore this will not affect interpretation of our results.
Our study has a number of strengths. We employed nation-
ally accepted definitions of rurality and have adjusted for local 
area deprivation. We have also measured presenteeism, which 
is increasingly recognised as commonly impacted by long- term 
conditions. However, productivity is difficult to define and 
existing self- reported measures of presenteeism (such as the 
Work Productivity and Activity Impairment, Health and Work 
Performance Questionnaire, Work Limitations Questionnaire, 
and Work Ability Index) have poor validity against objective 
markers and against each other39 40 and are oversimplistic in 
understanding work disability. Outcome Measures in Rheuma-
tology Clinical Trials (OMERACT) colleagues41 have reached 
similar conclusions and stressed the relevance and importance of 
‘contextual factors’ on impact from a health condition on work, 
for example, type of work, environment, and degree of flexibility 
. Our mixed- methods study adds quantitative and qualitative 
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evidence about the relevance and nature of clinical and contex-
tual factors, offering new insights into how features of occupa-
tions, individuals and workplaces influence work disability in 
axSpA. It illustrates the need for newer measures that do not 
take a self- assessed percentage loss approach but gauge impacts 
of health on work in a more comprehensive fashion.
In keeping with other studies, we found that patients with 
axSpA report significant levels of presenteeism,7 8 42 particularly 
in public- facing jobs (healthcare and hospitality), where there 
is a greater perception of ‘letting others down’.43–45 Others 
recognised that presenteeism was therapeutic, allowing them to 
maintain their social contact and sense of self- worth. Indeed, in 
a study of young adults with axSpA, they emphasised that work 
was a priority for them in order to establish a career, financially 
support young family and maintain identity.46
Our finding that rural dwellers have more issues with work 
productivity is novel but perhaps not surprising. Rural settings 
have both more restrictive labour markets alongside greater diffi-
culties for individuals accessing local healthcare services.9 13–16 
Our rural dwellers were older and more likely to be doing phys-
ically demanding occupations. This suggests that they have less 
flexibility to access work more suitable for their health. Many 
people living in rural settings were travelling to urban settings 
to work, suggesting another important issue for rural dwellers is 
the need to commute as well as undertake their work each day.
Emergent themes were coherent with the model of demand- 
control and support proposed by Karasek and Theorell.47 
Karasek and Theorell 47postulated that people could tolerate very 
high levels of workplace mental and physical demands providing 
that they were offered autonomy and control over how to work 
and support from colleagues and managers to deliver their work. 
Among people with axSpA, we found flexibility about work 
tasks was a key enabler of ongoing work participation. Similarly, 
while not specifically focused on work, other qualitative studies 
in axSpA have highlighted the need for flexibility to adapt daily 
working practices in response to unpredictable flares, as well 
as influencing choice of career and decisions to change job.46 48 
Career flexibility was important, especially in those with more 
physical jobs.46 While we found that work colleagues were a 
source of considerable support in enabling task flexibility, other 
studies have reported that unsatisfactory or slow work was a 
source of potential conflict with colleagues and employers.49 The 
differing ways in which people now participate with work also 
raise questions about how we define presenteeism, sick absence 
and fitness for work.
Our findings have important implications for practice, policy 
and research. Healthcare professionals could do much more to 
support their patients to work well, and resources are becoming 
available to support this.50 Most employers will have very few 
employees with rheumatic disease, and do not understand the 
often unpredictable disease course, and relapsing and remitting 
trajectory. Education and support for employers to enable flexi-
bility at work could be transformative, particularly if ‘best prac-
tice’ examples from other employers were made available.
New work measures are needed to capture important contex-
tual factors and comprehensively determine the impact of long- 
term conditions in the workplace, specifically taking account of 
the different ways in which people now engage in work. More 
broadly the role of geographical location in health and work 
outcomes in rheumatic disease is another important area for 
future research. The current European League Against Rheuma-
tism axSpA recommendations (which emphasise that improving 
quality of life is the key aim) are focused only on disease activity 
and function.51 Future recommendations should include support 
to work well as a target for management to optimise quality of 
life in patients with axSpA.
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